HELPLINE 443-864-4372

“Successfully treated over 120,000 patients, 94% of them go home catheter free!”

The Prolieve® Transurethral ThermoDilatation™ Therapy (TUTD™) offers a unique “Thermo+Dilatation” treatment for symptoms of enlarged prostate, also known as benign prostatic hyperplasia (BPH). Prolieve® is FDA approved and is the least invasive BPH treatment on the market.

With the balloon compressing the prostate, Prolieve® is a dual modality therapy simultaneously treating the gland with Focused Heat and Dilatation. With the 5-Year patient follow up approved and accepted by FDA in 2018,  Prolieve® has been proven fast, safe and effective.

94% of the patients do not require a post treatment catheter and the associated risks including retrograde ejaculation and erectile dysfunction are extremely low. Majority of patients experience significant and immediate relief, and the treatment results are also sustainable.

The treatment is a 45-minute, in-office, outpatient procedure which is performed and well-tolerated under local anesthesia. There is no need to go to the hospital and patients can return to their normal daily life right after the treatment.

 

Our Prolieve TUTD Advantages Over Other Minimally-Invasive BPH Therapies

Proven Immediate Symptom Relief & Long-Term Safety, Efficacy & Durability Yes
Appealing to Patients: Fewer Post-Treatment Catheterization Yes
No Foreign Bodies or Clips left within the Urinary Tract Yes
No Puncture of Prostatic Urethra to minimize Pain & Hemorrhage Yes
No/Minimal Sexual Side Effects (E.D. & Retrograde Ejaculation) Yes
Rectal Temperature Monitoring for Added Safety to the rectum & neurovascular bundles Yes
Our Experienced Technicians assist you in performing treatments in the Comfort of Your Office Yes

FDA Post Approval 5-Year Follow-up Study Completed & Accepted “Prevention of BPH Progression By Stabilizing PSA & Prostate Volume”

Post-Treatment Catheter-Free Rate 85%
Stabilization of BPH Symptoms 83% reported No Progression at Year 5
Erectile Dysfunction/Retrograde Ejaculation 0.3 per 100 person-years
Significant Improvement of Mean AUA Symptom Score Baseline = 20.1 vs. Year 5 = 12.8
Significant Improvement of Peak Flow Rate (Qmax) Baseline = 8.6 mL/s vs. Year 5 = 12.8 mL/s
Significant Improvement of Quality of Life (QOL) Score Baseline = 22 vs. Year 5 = 16

contact_graphic_home

© 2024 Medifocus Inc. | All rights reserved. | Important Information | Private Policy | Developed by Kohn Creative
go to top